Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety...

Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast Full year 2018 preliminary performance in line with recently revised guidanceFull year 2019 forecast reflects continued growth of organic business and anticipated positive impact of recent...